Europe
Oxurion NV announced today that it will give two presentations at the Euretina International Congress, which is being held in Vienna, Austria, from 20 to 23 September 2018.
CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.
Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial on Sunday that showed its triple combination therapy PT010 outperformed its dual-therapy rivals eight of nine times.
Owlstone Medical Ltd. announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
Ergomed plc will announce its interim results for the six months ended 30 June 2018 on Wednesday 19th September 2018.
Optimized production process delivering critical improvements for future commercial use to be applied to all allogeneic platform clinical trials
Preliminary anti-tumor activity for lead asset, monalizumab, in combination with cetuximab in advanced head and neck cancer and durvalumab in microsatellite-stable colorectal cancer presented at medical conferences
Let’s take a look at some of the professionals moving to transition the pharma and biotech world this past week.
Dublin-based Allergan is acquiring Newport Beach, California-based Bonti with an upfront payment of $195 million.
Company Marks its Eleventh Consecutive Year on the North American Dow Jones Sustainability Index (DJSI)
PRESS RELEASES